Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize

被引:478
作者
Fukumura, Dai
Jain, Rakesh K.
机构
[1] Massachusetts Gen Hosp, Edwin L Steele Lab Tumor Biol, Dept Radiat Oncol, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA 02114 USA
关键词
microenvironment; hypoxia; acidosis; interstitial fluid pressure; angiogenesis; microcircualtion; lymphangiogenesis; lymphatic metastasis; stromal cells; vascular endothelial growth factor; intravital microscopy;
D O I
10.1002/jcb.21187
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A solid tumor is an organ-like entity comprised of neoplastic cells and non-transformed host stromal cells embedded in an extracellular matrix. The expression of various genes is influenced by interactions among these cells, surrounding matrix, and their local physical and biochemical microenvironment. The products encoded by these genes, in turn, control the pathophysiological characteristics of the tumor, and give rise to the abnormal organization, structure, and function of tumor blood vessels. These abnormalities contribute to heterogeneous blood flow, vascular permeability, and microenvironment. Proliferating tumor cells produce solid stress which compresses blood and lymphatic vessels. As a result of vessel leakiness and lack of functional lymphatics, interstitial fluid pressure is significantly elevated in solid tumors. Each of these abnormalities forms a physiological barrier to the delivery of therapeutic agents to tumors. Furthermore, the metabolic microenvironment in tumors such as hypoxia and acidosis hinder the efficacy of anti-tumor treatments such as radiation therapy and chemotherapy. A judicious application of anti-angiogenic therapy has the potential to overcome these problems by normalizing the tumor vessels and making them more efficient for delivery of oxygen and drugs. Combined anti-angiogenic and conventional therapies have shown promise in the clinic.
引用
收藏
页码:937 / 949
页数:13
相关论文
共 78 条
[31]   Interstitial pH and pO(2) gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation [J].
Helmlinger, G ;
Yuan, F ;
Dellian, M ;
Jain, RK .
NATURE MEDICINE, 1997, 3 (02) :177-182
[32]   Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment [J].
Hobbs, SK ;
Monsky, WL ;
Yuan, F ;
Roberts, WG ;
Griffith, L ;
Torchilin, VP ;
Jain, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) :4607-4612
[33]   Tumor hypoxia:: Definitions and current clinical, biologic, and molecular aspects [J].
Höckel, M ;
Vaupel, P .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) :266-276
[34]   Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: Therapeutic implications. [J].
Hoshida, Tohru ;
Isaka, Naohide ;
Hagendoorn, Jeroen ;
di Tomaso, Emmanuelle ;
Chen, Yen-Lin ;
Pytowski, Bronislaw ;
Fukumura, Dai ;
Padera, Timothy P. ;
Jain, Rakesh K. .
CANCER RESEARCH, 2006, 66 (16) :8065-8075
[35]   Trimodal cancer treatment:: Beneficial effects of combined antianglogenesis, radiation, and chemotherapy [J].
Huber, PE ;
Bischof, M ;
Jenne, J ;
Heiland, S ;
Peschke, P ;
Saffrich, R ;
Gröne, HJ ;
Debus, J ;
Lipson, KE ;
Abdollahi, A .
CANCER RESEARCH, 2005, 65 (09) :3643-3655
[36]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[37]   Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts [J].
Inai, T ;
Mancuso, M ;
Hashizume, H ;
Baffert, F ;
Haskell, A ;
Baluk, P ;
Hu-Lowe, DD ;
Shalinsky, DR ;
Thurston, G ;
Yancopoulos, GD ;
McDonald, DM .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (01) :35-52
[38]   Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function [J].
Isaka, N ;
Padera, TP ;
Hagendoorn, J ;
Fukumura, D ;
Jain, RK .
CANCER RESEARCH, 2004, 64 (13) :4400-4404
[39]   Tumor biology - Herceptin acts as an anti-angiogenic cocktail [J].
Izumi, Y ;
Xu, L ;
di Tomaso, E ;
Fukumura, D ;
Jain, RK .
NATURE, 2002, 416 (6878) :279-280
[40]  
Jain R.K, 1995, US Patent Number, Patent No. [5396897, 5,396,897]